Letter ·
NAMD Provides Thoughts on High-Cost Drugs to Senate Finance
In March 2016, NAMD responded to a Senate Finance Committee Request for Information on prescription drug costs and coverage.
In March 2016, NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these drugs on the Medicaid program.
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.